Imaging of EGFR and EGFR Tyrosine Kinase Overexpression in Tumors by Nuclear Medicine Modalities

Publisher： Bentham Science Publishers

E-ISSN： 1873-4286|14|28|2983-2998

ISSN： 1381-6128

Source： Current Pharmaceutical Design, Vol.14, Iss.28, 2008-10, pp. : 2983-2998

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Rational Design of Potent and Selective EGFR Tyrosine Kinase Inhibitors as Anticancer Agents

By  

Current Cancer Drug Targets, Vol. 1, Iss. 2, 2001-08 ,pp. : 129-140

Bentham Science Publishers

Access to resources Recommend Favorite

Novel Substituted Quinazolines for Potent EGFR Tyrosine Kinase Inhibitors

By  

Current Medicinal Chemistry, Vol. 18, Iss. 7, 2011-03 ,pp. : 943-963

Bentham Science Publishers

Access to resources Recommend Favorite

Development of the Third Generation EGFR Tyrosine Kinase Inhibitors for Anticancer Therapy

By  

Current Medicinal Chemistry, Vol. 23, Iss. 29, 2016-10 ,pp. : 3343-3359

Bentham Science Publishers

Access to resources Recommend Favorite

The Role of EGFR Tyrosine Kinase Inhibitors in the First-Line Treatment of Advanced Non Small Cell Lung Cancer Patients Harboring EGFR Mutation

By  

Current Medicinal Chemistry, Vol. 19, Iss. 20, 2012-07 ,pp. : 3337-3352

Bentham Science Publishers

Access to resources Recommend Favorite

The EGFR tyrosine kinase inhibitor tyrphostin AG-1478 causes hypomagnesemia and cardiac dysfunction

By Weglicki William B.   Kramer Jay H.   Spurney Christopher F.   Chmielinska Joanna J.   Mak I. Tong  

Canadian Journal of Physiology and Pharmacology, Vol. 90, Iss. 8, 2012-08 ,pp. : 1145-1149

NRC Research Press

Access to resources Recommend Favorite